A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06732154
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06723691
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06654960
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT06650007
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 840
- Registration Number
- NCT06649344
- Locations
- 🇨🇳
Zhu Xianyi Memorial Hospital,Tianjin Medical University, Tianjin, Tianjin, China
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06595797
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT06565871
HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 700
- Registration Number
- NCT06554184
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center Yuexiu Campus, Guangzhou, Guangdong, China
A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06541457
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06506994
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath